Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00103701 · ClinicalTrials.gov registry record · Phase 1
BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00103701 is a Phase 1 study that has completed, run by Bristol-Myers Squibb.
The verdict
NCT00103701, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
The purpose of this clinical research study is to understand the safety and efficacy of BMS-354825 in patients with chronic, accelerated, or blast phase chronic myelogenous leukemia (CML) or Philadelphia positive acute lymphoblastic leukemia (ALL) who are resistant to or intolerant of imatinib mesylate (Gleevec).
Interventions
- DRUG Dasatinib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-11 |
| Est. Completion | 2006-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00103701
The ClinicalTrials.gov registry entry for NCT00103701 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dasatinib is the first listed.
NCT00103701 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00103701 about?
NCT00103701 is a clinical study titled "BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia". The purpose of this clinical research study is to understand the safety and efficacy of BMS-354825 in patients with chronic, accelerated, or blast phase chronic myelogenous leukemia (CML) or Philadelphia positive acute lymphoblastic leukemia (ALL) who are resistant to or intolerant of imatinib mesyl...
What is the current status of trial NCT00103701?
This trial is currently completed. It is a Phase 1 study. The study started on 2003-11. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00103701?
The interventions under investigation include: Dasatinib (DRUG).
Who is sponsoring clinical trial NCT00103701?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.